Following Michael Rice’s last BLFS Sell transaction on February 16, 2018, the stock climbed by 10.6%. This is Rice’s first Sell trade following 3 Buy transactions.
Based on BioLife Solutions’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $6.6 million and quarterly net profit of $9.32 million. In comparison, last year the company earned revenue of $5.46 million and had a net profit of $893K. The company has a one-year high of $22.44 and a one-year low of $11.60. BLFS’s market cap is $328.9M and the company has a P/E ratio of 34.99.
The insider sentiment on BioLife Solutions has been positive according to 79 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Michael Rice’s trades have generated a 51.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.